NCT00056368已完成3 期
A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 256
- 试验地点
- 2
研究概览
简要总结
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
详细描述
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17NeutropeniaNCT00056381Pfizer25
已完成
3 期
Anidulafungin Versus Fluconazole in the Treatment of CandidemiaCandidaCandidiasisNCT00058682National Cancer Institute (NCI)248
已完成
2 期
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.CandidiasisNCT00037219Pfizer120
已完成
2 期
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)CandidiasisNCT00041704Pfizer19
尚未招募
不适用
Study of skin features, laboratory features and response to treatment to antifungal drugs in patients with superficial fungal infections.CTRI/2018/04/013045MAHARAJAHS INSTITUTE OF MEDICAL SCIENCES